Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pediatric trial of adjuvanted cell culture-derived H5N1 influenza vaccine (two formulations)
2021-004813-37Phase 2
- Sponsor
- CSL Seqirus
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of MF59-eH5N1 in Influenza A H5N1 infection (H5N1) and influenza (2 arms), sponsored by CSL Seqirus. Primary endpoints: Primary immunogenicity endpoints and Safety and tolerability endpoints.
02
Drugs
MF59-eH5N1
03
Conditions
Influenza A H5N1 infection (H5N1)influenza
Beyond the preview
Go deeper on 2021-004813-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004813-37.